BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/22/2021 9:56:11 AM | Browse: 261 | Download: 478
 |
Received |
|
2021-04-16 21:30 |
|
Peer-Review Started |
|
2021-04-16 21:34 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-07-06 01:18 |
|
Revised |
|
2021-07-29 12:44 |
|
Second Decision |
|
2021-09-14 03:39 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-09-17 02:05 |
|
Articles in Press |
|
2021-09-17 02:05 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-10-19 12:17 |
|
Publish the Manuscript Online |
|
2021-10-22 09:56 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Miguel J Sotelo, José Luis García, Cesar Torres-Mattos, Héctor Milián, Carlos Carracedo, María Ángeles González-Ruiz, Xabier Mielgo-Rubio, Juan Carlos Trujillo-Reyes and Felipe Couñago |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Miguel J Sotelo, MD, PhD, Consultant Physician-Scientist, Department of Medical Oncology, Hospital María Auxiliadora, Oncological Research Unit, Clínica San Gabriel, Avda Miguel Iglesias 968, Lima 15801, Peru. miguel.sotelo.lezama@gmail.com |
| Key Words |
Non-small-cell lung cancer; Early stage; Epidermal growth factor receptor-mutated; Epidermal growth factor receptor-mutated-tyrosine kinase inhibitor; Adjuvant; Neoadjuvant |
| Core Tip |
Epidermal growth factor receptor-mutated (EGFR) tyrosine kinase inhibitors (TKIs) have changed the natural history of advanced EGFR-mutated non-small-cell lung cancer (NSCLC). Multiple clinical trials conducted in the adjuvant setting have shown that EGFR TKIs prolong disease-free survival (DFS) but not overall survival (OS). Osimertinib demonstrated a surprising improvement in DFS in an interim analysis of the ADAURA study, which led to the study being stopped early, and left many unanswered questions about its potential effect on OS. Locally-advanced disease is also an attractive situation for assessment of the efficacy of these agents, with encouraging results so far. We discuss the recent advances in the management of early-stage EGFR-mutated NSCLC. |
| Publish Date |
2021-10-22 09:56 |
| Citation |
Sotelo MJ, Luis García J, Torres-Mattos C, Milián H, Carracedo C, González-Ruiz MA, Mielgo-Rubio X, Trujillo-Reyes JC, Couñago F. Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer. World J Clin Oncol 2021; 12(10): 912-925 |
| URL |
https://www.wjgnet.com/2218-4333/full/v12/i10/912.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v12.i10.912 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
